On 21 September, Perfect World Digital Art hosted Beyond Extreme: A China–Sweden Games & Esports Exchange Event at Nationalmuseum in Stockholm. The event brought together industry and academic representatives from China and Sweden to discuss games, esports, digital culture and future cross-border collaboration, alongside the world premiere of the esports digital-fashion collection Six Symbols Competitive Overture. STOCKHOLM, Oct. 14, 2026 (GLOBE NEWSWIRE) — Beyond Extreme: A China–Sweden Games & Esports Exchange Event, hosted by Perfect World Digital Art, was successfully held at Nationalmuseum in Stockholm. Bringing together representatives from industry and academia, the event explored how games, esports and digital culture can foster dialogue between China and Sweden, shape younger generations and create opportunities...

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal diseases REYKJAVIK, Iceland and LONDON, UK (October 14, 2026) – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea® 8 mg (aflibercept 114.3 mg/mL), which is marketed as Eylea HD® in the United States. Based on publicly available...

AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal diseases REYKJAVIK, Iceland and LONDON, Oct. 14, 2026 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma Holdco Limited (“Advanz Pharma”), a global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced the submission of a European regulatory application for AVT29, a proposed biosimilar to Eylea® 8 mg (aflibercept 114.3 mg/mL), which is marketed as Eylea HD® in the United States. Based on...

Press Release Atos expands partnership with Fortinet to deliver a global unified cybersecurity framework across hybrid and multi-cloud environments Paris, France – October 14, 2026 – Atos, a global leader of AI-powered digital transformation, today announces that it is expanding its longstanding partnership with Fortinet, a global cybersecurity leader, from a country-led to a global engagement model. The agreement will help organizations strengthen security across hybrid and multi-cloud environments worldwide through a unified framework including reselling and managed cybersecurity services. It will also align joint business development, customer engagement, service delivery and competitive commercial terms globally to address organizations’ growing cybersecurity challenges. Clients contend with escalating cyber threats and ransomware...

Synmosa to lead regulatory approvals, market access, distribution and sales in Singapore, Thailand, Indonesia, Malaysia, the Philippines, Vietnam, Australia and New Zealand. Nxera to supply drug product and receive an upfront payment, regulatory approval milestones, royalties and product supply revenue. Agreement significantly expands potential access to QUVIVIQ® across Asia-Pacific, building on progress in Japan, Taiwan and South Korea.Tokyo, Japan and Cambridge, UK, 14 October 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”; TSE: 4565) today announces that its subsidiary, Nxera Pharma Japan Co., Ltd. (“Nxera Pharma Japan”), has entered into an exclusive license, supply and commercialization agreement (the “Agreement”) with Taiwan-headquartered Synmosa Biopharma Corporation (“Synmosa”) for QUVIVIQ® (daridorexant), a treatment...

BERLIN, Oct. 14, 2026 (GLOBE NEWSWIRE) — Vattenfall and Fluence Energy, Inc.  (“Fluence”) (NASDAQ: FLNC), a global market leader delivering intelligent energy storage systems, services, and asset optimization software, have signed an agreement for the delivery of the planned battery storage facility in Brunsbüttel, as well as long-term service support. With an output of 254 MW and a storage capacity of over 1,000 MWh, the Brunsbüttel project, which is planned to be built at the site of the nuclear power plant that is currently being decommissioned, is expected to be among the largest battery energy storage projects in Germany and represents Vattenfall’s largest battery project to date. The project is scheduled to become operational by the end of 2028. The 4-hour storage facility will utilize Fluence’s Gridstack™...

TOKYO, Oct. 14, 2026 (GLOBE NEWSWIRE) — Leading semiconductor test equipment supplier Advantest Corporation (TSE: 6857) today announced a global call for papers for its VOICE 2027 Developer Conference, focusing on leading-edge technologies and future trends. The conference will be held in San Jose, Calif., at the Signia by Hilton on June 14-16, 2027. VOICE is the leading conference for the growing global community of users and strategic partners involved with Advantest’s V93000 and T2000 SoC test platforms, handlers, test cell solutions, product engineering and technology development. The annual conference brings together semiconductor test professionals representing the world’s leading integrated device manufacturers (IDMs), foundries, fabless semiconductor companies and outsourced semiconductor assembly and test (OSAT) providers...

New AR email agent reads, understands and acts on customer correspondence, extending Quadient’s AI-native finance automation platform while keeping finance teams in complete control PARIS – Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, today announced the launch of its AR email agent, expanding agentic AI capabilities into Quadient’s accounts receivable (AR) solution. The new capability reads incoming customer emails, identifies customer intent and prepares appropriate actions, helping finance teams reduce manual work while maintaining control over every customer interaction. Finance teams get a step change in productivity without giving up oversight. The launch is the latest step in Quadient’s strategy to build finance automation around purpose-built AI agents rather...

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE, 14 OCTOBER 2026 AT 9:50 AM EEST / CHANGES IN BOARD/MANAGEMENT/AUDITORS Karri Alameri will leave his position as Chief Executive Officer of Oma Savings Bank Plc Oma Savings Bank Plc (“OmaSp” or the “Company”) and Karri Alameri have mutually agreed that Alameri will leave his position as the Chief Executive Officer of the Company on 5 November 2026, such that his employment relationship with the Company will end on 5 May 2027. Alameri will stand for election to the Board of Directors of OmaSp. OmaSp’s Board of Directors will commence a process for nominating a new Chief Executive Officer. Oma Savings Bank PlcFor further information: Jaakko Ossa, Chairman of the Board of Directors, interview requests via CCO Karri Alameri, CEO, tel. +358 20 758 3040, karri.alameri@omasp.fi Pirjetta...